• Pharmacokinetic endpoints: area under the insulin concentration curve (AUCins) 0-24h [ Time Frame: 0-24hour ]
  area under the insulin concentration curve
• Pharmacokinetic endpoints: insulin concentration (Cins).max [ Time Frame: 0-24hour ]
  maximum observed insulin concentration.
• Pharmacodynamic Endpoint: Area under curve (AUC)Glucose infusion rate (GIR).0-24h [ Time Frame: 0-24hour ]
  area under the glucose infusion rate curve
• Pharmacodynamic Endpoint: maximum glucose infusion rate (GIRmax) [ Time Frame: 0-24hour ]
  maximum glucose infusion rate

• Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins) 0-2h [ Time Frame: 0-2hour ]
  area under the insulin concentration curve
• Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins) 0-6h [ Time Frame: 0-6hour ]
  area under the insulin concentration curve
• Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins) 0-12h [ Time Frame: 0-12hour ]
  area under the insulin concentration curve
• Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins)12-24h [ Time Frame: 12-24hour ]
  area under the insulin concentration curve
• Pharmacokinetic endpoint: area under the insulin concentration curve(AUCins).0-infinity [ Time Frame: 0 to 24 hours ]
  area under the insulin concentration curve
• Pharmacokinetic endpoint: time to maximum observed insulin concentration (tmax) [ Time Frame: 0-24hour ]
  time to maximum observed insulin concentration
• Pharmacokinetic endpoint: time(t)50%-ins(early) [ Time Frame: 0-24hour ]
  time to half-maximum before Cins.max
• Pharmacokinetic endpoint: time(t)50%-ins(late) [ Time Frame: 0-24hour ]
  time to half-maximum after Cins.max
• Pharmacokinetic endpoint: terminal elimination half-life (t½) [ Time Frame: 0-24hour ]
  terminal elimination half-life calculated as t½=ln2/λz
• Pharmacokinetic endpoint:terminal elimination rate constant(λz) [ Time Frame: 0-24hour ]
  terminal elimination rate constant of insulin
• Pharmacodynamic endpoints: area under the glucose infusion rate curve (AUCGIR) 0-2h [ Time Frame: 0-2hour ]
  area under the glucose infusion rate curve
• Pharmacodynamic endpoints: area under the glucose infusion rate curve (AUCGIR)0-6h [ Time Frame: 0-6hour ]
  area under the glucose infusion rate curve
• Pharmacodynamic endpoints: area under the glucose infusion rate curve(AUCGIR)0-12h [ Time Frame: 0-12hour ]
  area under the glucose infusion rate curve
• Pharmacodynamic endpoints: area under the glucose infusion rate curve (AUCGIR)12-24h [ Time Frame: 12-24hour ]
  area under the glucose infusion rate curve
• Pharmacodynamic endpoints: time to maximum glucose infusion rate (tGIR.max) [ Time Frame: 0-24hour ]
  time to maximum glucose infusion rate
• Pharmacodynamic endpoints: time to half-maximum glucose infusion rate before GIRmax(tGIR.50%-early) [ Time Frame: 0-24hour ]
  time to half-maximum glucose infusion rate before Maximum glucose infusion rate(GIRmax)
• Pharmacodynamic endpoints: time to half-maximum glucose infusion rate after GIRmax (tGIR.50%-late) [ Time Frame: 0-24hour ]
  time to half-maximum glucose infusion rate after Maximum glucose infusion rate(GIRmax)
• Pharmacodynamic endpoints: Onset of action [ Time Frame: 0-24hour ]
  time from trial product administration until blood glucose concentration has decreased at least 5 mg/dL from baseline, where baseline is defined as the mean of blood glucose levels from -6, -4, and -2 minutes before trial product administration as measured by ClampArt(name of Clamp Devise).

• Safety endpoints: Number of subjects with Adverse Events, clinically significant changes in Physical examination, Vital signs. Local tolerability/ Injection site reactions [ Time Frame: First dose to followup period (Total duration: 14 days approximate) ]
  Number of subjects with Adverse Events, clinically significant changes in Physical examination, Vital signs Local tolerability/ Injection site reactions
• Safety endpoint: Number of subjects with clinically significant changes in Laboratory safety parameters, Electrocardiogram (ECG) [ Time Frame: Screening and Follow-up period (Total duration: 35 days approximate) ]
  Number of subjects with clinically significant changes in Laboratory safety parameters. Number of subjects with clinically significant changes in Electrocardiogram (ECG)

The present study is designed to demonstrate pharmacokinetic and pharmacodynamic equivalence of Biocon Insulin 70/30 with Humulin® 70/30 in healthy subjects The treatment consists of one single dose of the test or reference product, administered during each of the two study periods, separated by 5-7 days between dosing. The planned trial duration for each subject is about 12 to 36 days.

Eligible subjects will undergo two 24-hour euglycaemic clamp examinations, one after administration of the test product and one after administration of the reference product in random order.

• Biological: Humulin ®70/30

  Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.

  Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli.

• Biological: Biocon Insulin 70/30

  Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.

  Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli.

• Experimental: Biocon Insulin 70/30
  0.4 IU/kg Dose per administration, Subcutaneous Route of administration
  Intervention: Biological: Biocon Insulin 70/30
• Active Comparator: Humulin® 70/30
  0.4 IU/kg Dose per administration, Subcutaneous Route of administration
  Intervention: Biological: Humulin ®70/30

Inclusion Criteria:

• Healthy male or post-menopausal female subjects. Post-menopausal state is defined as no menses for 12 months without an alternative medical cause and confirmed by a follicle stimulating hormone (FSH) level in the post-menopausal range (>= 25.8 IU/L).
• Age between 18 and 55 years, both inclusive.
• Body Mass Index (BMI) between 18.5 and 29.0 kg/m^2, both inclusive.
• Fasting plasma glucose concentration <= 100 mg/dL.
• Considered generally healthy upon completion of medical history and screening safety assessments, as judged by the Investigator.

Exclusion Criteria:

• Known or suspected hypersensitivity to Investigational Medicinal products ((IMP(s)) or related products.
• Receipt of any medicinal product in clinical development within 30 days or five times its half-life (whichever is longer) before randomization in this trial.
• Any history or presence of clinically relevant comorbidity, as judged by the investigator.
• Systolic blood pressure < 95 mmHg or >140 mmHg and/or diastolic blood pressure < 50 mm Hg or > 90 mmHg after resting for at least 5 minutes in supine position (excluding white-coat hypertension; therefore, a repeat test showing results within range will be acceptable).
• Pulse rate at rest outside the range of 50-90 beats per minute.